Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study

Table 6 Side effects (n = 1375) n (%)

Side effects	SOF + RBV (n = 847)	SOF + RBV + Peg (n = 528)	P value
Headache	248 (29.28)	198 (37.50)	0.083
Fatigue	147 (17.36)	168 (31.82)	0.001
Myalgia	38 (4.49)	43 (8.14)	0.830
Hashimoto's thyroiditis	2 (0.23)	1 (0.19)	0.001
Decreased appetite	71 (8.38)	89 (16.86)	0.179
Rash	7 (0.82)	3 (0.57)	0.001
Thrush	23 (2.71)	19 (3.60)	0.467
Hair loss	8 (0.94)	59 (11.17)	0.781
Aggressiveness	29 (3.42)	38 (7.20)	0.895
Pruritus	69 (8.14)	57 (10.79)	0.959
Insomnia	79 (9.32)	63 (11.93)	0.498
Depression	36 (4.25)	67 (12.69)	0.006
Acute psychosis	8 (0.94)	3 (0.57)	0.776
Hematologic abnormalities
Anemia (< 10 g/dL)	238 (28.10)	215 (40.72)	0.001
Leukocytopenia (< 3 × 103/μL)	16 (1.89)	61 (11.55)	0.001
Thrombocytopenia (< 100 × 103/μL)	64 (7.56)	72 (13.64)	0.188
Bell’s Palsy	3 (0.35)	1 (0.19)	0.628
Intracranial hemorrhage	2 (0.23)	0 (0)